MatthewJMatasarMD(He/Him)

PubMed

• Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
  Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2024 Mar 28
• 1 citations
  Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
  Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, Victor Maximov, Andrew G Polson, Katerina Hatzi, Elisabeth A Lasater, Sarit E Assouline, Nancy L Bartlett, L Eli...> ;Blood. 2024 Feb 29
• Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy i...
  Lin, S., Shapouri, S., Parisé, H., Bercaw, E., Wu, M., Kim, E., Matasar, M.> ;Pharmacoeconomics. 2024 Feb 1
• Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP.
  Bantilan, K., Smith, A., Maurer, M., Teruya-Feldstein, J., Matasar, M., Moskowitz, A., Straus, D., Noy, A., Palomba, M., Horwitz, S., Hamlin, P., Portlock, C., Cerhan,...> ;Blood Advances. 2024 Jan 25
• Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
  Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, Lihua E Budde, Ian Flinn, Gareth P Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S Diefenbach, Huan...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Apr 1
• Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.
  Christopher R Flowers, Matthew J Matasar, Alex F Herrera, Mark Hertzberg, Sarit Assouline, Judit Demeter, Andrew McMillan, Amitkumar Mehta, Stephen Opat, Marek Trnňný,...> ;Haematologica. 2024 Apr 1
• Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
  Parastoo B Dahi, Sheila Kenny, Jessica Flynn, Sean M Devlin, Josel D Ruiz, Stephanie A Chinapen, Oscar B Lahoud, Matthew J Matasar, Craig H Moskowitz, Miguel-Angel Per...> ;Leukemia & Lymphoma. 2023 Dec 1
• US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
  Matthew Matasar, Anthony Masaquel, Rodrigo S Ho, Aino Launonen, Carmen D Ng, Rongrong Wang, David Fox, Farah Hossain, Jia Li, John M Burke> ;Journal of Medical Economics. 2023 Sep 7
• Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
  Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus, M Lia Palomba, Ali...> ;Haematologica. 2024 Jan 1
• Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
  John M Burke, Anthony Masaquel, Rongrong Wang, Farah Hossain, Jia Li, Summera Qiheng Zhou, Carmen D Ng, Matthew Matasar> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
• 1 citations
  Retrospective characterization of nodal marginal zone lymphoma.
  Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin,...> ;Blood Advances. 2023 Sep 12
• 2 citations
  TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
  William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan...> ;Blood Advances. 2023 Sep 12
• 10 citations
  Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
  Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Y Cheah, Matthew Matasar, Gareth P Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-S...> ;Blood Advances. 2023 Sep 12
• Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
  Michael J Buege, Esther Drill, Steven M Horwitz, Andréa LeVoir, Terry Pak, Tim J Peterson, Phuong H Dao, Matthew J Matasar> ;European Journal of Haematology. 2023 Jul 1
• 2 citations
  Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.
  Serena Zheng, Kanika Gupta, Piyush Goyal, Reiko Nakajima, Laure Michaud, Connie Lee Batlevi, Paul A Hamlin, Steven Horwitz, Anita Kumar, Matthew J Matasar, Alison J Mo...> ;Cancers. 2023 Mar 14
• 3 citations
  Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma withormutations: an open label phase II study.
  David Qualls, Ariela Noy, David Straus, Matthew Matasar, Craig Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Ba...> ;Leukemia & Lymphoma. 2023 Mar 1
• 1 citations
  Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
  David Qualls, Brandon S Imber, Michelle Okwali, Paul A Hamlin, Anita Kumar, Oscar B Lahoud, Matthew J Matasar, Ariela Noy, Colette Owens, Andrew D Zelenetz, Victoria S...> ;British Journal of Haematology. 2023 Feb 1
• Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors.
  Talya Salz, Emily C Zabor, Peter De Nully Brown, Susanne Oksbjerg Dalton, Nirupa J Raghunathan, Matthew J Matasar, Richard Steingart, Henrik Hjalgrim, Lena Specht, And...> ;Acta Oncologica. 2022 Sep 1
• Land(mark) ahoy: PFS24 in relapsed/refractory diffuse large B-cell lymphoma.
  Matthew Matasar> ;Transplantation and Cellular Therapy. 2022 Sep 1
• 1 citations
  PI3K inhibitors in haematological malignancies.
  Matthew J Matasar, Florian Hiemeyer, Barrett H Childs, Pier Luigi Zinzani> ;The Lancet. Oncology. 2022 Aug 1
• 75 citations
  Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
  Lihua E Budde, Laurie H Sehn, Matthew Matasar, Stephen J Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew ...> ;The Lancet. Oncology. 2022 Aug 1
• 7 citations
  Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
  Gita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gi...> ;The Lancet. Haematology. 2022 May 1
• 3 citations
  A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
  David Qualls, Hiu Ying Lam, Karissa Whiting, Anita Kumar, Matthew Matasar, Colette Owens, Chelsea Nichols, James A Espeleta, Annie Qiu, Sarima Subzwari, Erin Biggar, V...> ;Blood Advances. 2022 Sep 27
• 1 citations
  Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
  Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C Caron, Lorenzo Falchi, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar,...> ;Blood Cancer Journal. 2022 Feb 10
• 120 citations
  Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
  Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2022 Feb 10
• Join now to see all

Abstracts/Posters

• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit...
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018